A Canine Model to Evaluate Efficacy and Safety of γ-Secretase Inhibitors and Modulators

被引:11
作者
Borghys, Herman [1 ]
Tuefferd, Marianne [1 ]
Van Broeck, Bianca [1 ]
Clessens, Ellen [1 ]
Dillen, Lieve [1 ]
Cools, Willy [1 ]
Vinken, Petra [1 ]
Straetemans, Roel [1 ]
De Ridder, Filip [1 ]
Gijsen, Harrie [1 ]
Mercken, Marc [1 ]
机构
[1] Pharmaceut Companies Johnson & Johnson, Ctr Excellence Cardiovasc Safety & Mechanist Phar, Janssen Res & Dev, B-2340 Beerse, Belgium
关键词
Alzheimer's disease; amyloid-beta; dog; gamma-secretase; gene expression; liver; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; IN-VIVO; UNDERSTAND MECHANISMS; BETA PRODUCTION; DISCOVERY; CELLS; TOXICOGENOMICS; DEMENTIA;
D O I
10.3233/JAD-2011-111475
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gamma-secretase, a membrane bound protease which cleaves the transmembrane protein amyloid-beta protein precursor (A beta PP), is a therapeutic target for Alzheimer's disease. Gamma-secretase inhibitors (GSIs) and modulators (GSMs) are being investigated as potential disease-modifying agents. Preclinical in vivo models to monitor the activity on gamma-secretase are described in different species such as mouse, rat, and guinea pigs. All these models have their value in testing compounds with amyloid lowering properties, however, compound characteristics and pharmacokinetic properties, as well as other species characteristics such as limited sampling volumes of cerebrospinal fluid (CSF), recommended the use of a larger, non-rodent animal species. For this purpose, a screening model in dogs was developed for testing GSIs and GSMs. We showed that GSIs and GSMs had a dose- and time-dependent effect on A beta(37), A beta(38), A beta(40), and A beta(42) in CSF. Changes in liver function were evidenced by a transient increase in bilirubin with the GSMs and incidental increases in alanine aminotransferase for GSMs as well as GSIs. Microarray analysis of liver biopsies enabled to elucidate potential mechanisms behind the liver function changes. The relevance of the liver findings should be further evaluated in chronic pre-clinical safety studies and in humans. Based on our data, we can conclude that the dog is a very appropriate species to assess efficacy and safety of compounds which have an effect on A beta PP processing such as GSMs, GSIs, and BACE-inhibitors.
引用
收藏
页码:809 / 822
页数:14
相关论文
共 52 条
[1]   Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis [J].
Anderson, Nora ;
Borlak, Juergen .
PHARMACOLOGICAL REVIEWS, 2008, 60 (03) :311-357
[2]  
[Anonymous], 2011, R LANG ENV STAT
[3]  
Bates D., 2009, Mixed-Effects Models in S and S-PLUS
[4]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[5]   Amyloid β-protein (Aβ) assembly:: Aβ40 and Aβ42 oligomerize through distinct pathways [J].
Bitan, G ;
Kirkitadze, MD ;
Lomakin, A ;
Vollers, SS ;
Benedek, GB ;
Teplow, DB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (01) :330-335
[6]   Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development [J].
Blomme, Eric A. G. ;
Yang, Yi ;
Waring, Jeffrey F. .
TOXICOLOGY LETTERS, 2009, 186 (01) :22-31
[7]  
Buck Wayne R., 2008, V460, P23, DOI 10.1007/978-1-60327-048-9_2
[8]   E-Cadherin Antagonizes Transforming Growth Factor β1 Gene Induction in Hepatic Stellate Cells by Inhibiting RhoA-Dependent Smad3 Phosphorylation [J].
Cho, Il Je ;
Kim, Young Woo ;
Han, Chang Yeob ;
Kim, Eun Hyun ;
Anderson, Richard A. ;
Lee, Young Sok ;
Lee, Chang Ho ;
Hwang, Se Jin ;
Kim, Sang Geon .
HEPATOLOGY, 2010, 52 (06) :2053-2064
[9]   The Role of Amyloid Precursor Protein Processing by BACE1, the β-Secretase, in Alzheimer Disease Pathophysiology [J].
Cole, Sarah L. ;
Vassar, Robert .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (44) :29621-29625
[10]  
Cotman CW, 2008, J ALZHEIMERS DIS, V15, P685